CoChat

Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany

Steinig, Isabel, von Podewils, Felix, Möddel, Gabriel, Bauer, Sebastian, Klein, Karl Martin, Paule, Esther, Reif, Philipp S., Willems, Laurent M., Zöllner, Johann Philipp, Kunz, Rhina, Runge, Uwe, Kurlemann, Gerhard, Schubert‐Bast, Susanne, Rosenow, Felix, Strzelczyk, Adam · 2017 · Epilepsia
Cited by 115

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Summary: Objective: To evaluate factors predicting efficacy, retention, and tolerability of add‐on brivaracetam (BRV) in clinical practice. Methods: A multicenter, retrospective cohort study recruiting all patients who started BRV between February and November 2016 with observation time between 3 and 12 months. Results: Of a total of 262 patients (mean age 40, range 5–81 years, 129 male) treated with BRV, 227 (87%) were diagnosed to have focal, 19 (7%) idiopathic generalized and 8 (3%) symptomatic generalized epilepsy, whereas 8 (3%) were unclassified. The length of exposure to BRV ranged from 1 day to 12 months, with a median retention time of 6.1 months, resulting in a total exposure time to BRV of 1,504 months. The retention rate was 79.4% at 3 months and 75.8% at 6 months. Efficacy at 3 months was 41.2% (50% responder rate) with 14.9% seizure‐free for 3 months and, at 6 months, 40.5% with 15.3% seizure‐free. Treatment‐emergent adverse events were observed in 37.8% of the patients, with the most common being somnolence, dizziness, and behavioral adverse events (BAEs). BAE that presented under previous levetiracetam (LEV) treatment improved upon switch to BRV in 57.1% (20/35) and LEV‐induced somnolence improved in 70.8% (17/24). Patients with BAE on LEV were more likely to develop BAE on BRV (odds ratio [OR] 3.48, 95% confidence interval [CI] 1.53–7.95). Significance: BRV in broad clinical postmarketing use is a well‐tolerated anticonvulsant drug with 50% responder rates, similar to those observed in the regulatory trials, even though 90% of the patients included had previously been exposed to LEV. An immediate switch from LEV to BRV at a ratio of 10:1 to 15:1 is feasible. The only independent significant predictor of efficacy was the start of BRV in patients not currently taking LEV. The occurrence of BAE during previous LEV exposure predicted poor psychobehavioral tolerability of BRV treatment. A switch to BRV can be considered in patients with LEV‐induced BAE.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/epi.13768

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 115

Metadata

Authors
Steinig, I., von Podewils, F., Möddel, G., Bauer, S., Klein, K. M., Paule, E., Reif, P. S., Willems, L. M., Zöllner, J. P., Kunz, R., Runge, U., Kurlemann, G., Schubert‐Bast, S., Rosenow, F., & Strzelczyk, A.
Venue
Epilepsia
Publisher
Wiley
Published
2017-05-08
Volume
58
Issue
7
Pages
1208-1216
ISSN
  • 0013-9580 (ISSN-L)
  • 1528-1167
OpenAlex
W2613020156
Cited by
115
References
4
FWCI
11.56
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany. https://app.cochat.ai/papers/10.1111/epi.13768
The paper
Steinig, I., von Podewils, F., Möddel, G., Bauer, S., Klein, K. M., Paule, E., Reif, P. S., Willems, L. M., Zöllner, J. P., Kunz, R., Runge, U., Kurlemann, G., Schubert‐Bast, S., Rosenow, F., & Strzelczyk, A. (2017). Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany. Epilepsia. https://doi.org/10.1111/epi.13768

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.